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hnterpretation of Amino-Terminal
ro-Brain Natriuretic Peptide
evels in the HPS and the
ORONA Study
he Heart ProtectionStudy (HPS) reported that the use of
imvastatin reduced mortality in a broad range of patients with
ascular disease or diabetes and did not exclude patients with heart
ailure, although this diagnosis was not recorded (1,2). The authors
f the CORONA (Controlled Rosuvastatin Multinational Study
n Heart Failure) study failed to identify a reduction in mortality
ith rosuvastatin in predominantly elderly patients with heart
ailure due to left ventricular systolic dysfunction secondary to
schemic heart disease (3). Overall, the annual mortality was
pproximately 3% in the HPS trial and 12% in the CORONA
tudy.
Both studies reported plasma concentrations of amino-terminal
ro-brain natriuretic peptide (NT-proBNP), and both identified
hat patients with higher levels had a substantially greater rate of
ortality. The plasma concentration of NT-proBNP was mea-
ured in 20,536 patients in the HPS trial, with a reported median
alue of 1,091 pg/ml (interquartile range [IQR] 330 to 3,028
g/ml) and in 3,664 patients in the CORONA study with a
edian value of 170 pmol/l (IQR 71 to 380 pmol/l), which
orresponds to 1,438 pg/ml (IQR 600 to 3,214 pg/ml). In the HPS
rial, analysis of the prognostic importance of NT-proBNP was
onducted by dividing patients into 5 groups with an approxi-
ately equal number of cardiovascular events. The group with
he lowest risk, comprising 28% of all patients, had NT-
roBNP levels of 386 pg/ml, and their rate of major vascular
vents was 16.2% over the course of 5 years (about 4% per year),
hereas the 12% of patients who were in the highest-risk group
ad NT-proBNP values 5,579 pg/ml, and their rate of events
as 37.7% over the course of 5 years (about 7% per year). In the
ORONA study, the annual rate of major vascular events was
pproximately 7.7% per year in the lower 2 tertiles (2,348
g/ml) combined compared with 20.5% per year in the upper
ertile.
These data suggest that plasma concentrations of NT-proBNP
n studies designed to have a widely different prevalence of heart
ailure were rather similar, which is surprising. This anomaly is
xplained by differences in the assays used. In the HPS trial, the
uthors used a locally developed assay and in the CORONA study,
he authors used a commercially available one (Roche, Nutley,
ew Jersey). The conversion factor between assays (reporting in
icograms per milliliter) is not linear. For instance, cut-offs used in
he HPS trial of 386 and 5,758 pg/ml correspond to 68 and 728
g/ml in the CORONA study, whose authors used the Roche
ssay. The median value and IQR in the HPS trial would have sorresponded to approximately 168 pg/ml (IQR 58 to 422 pg/ml)
hen using the Roche assay. Therefore, the overlap between
lasma NT-proBNP concentrations in the HPS trial and the
ORONA study is modest (Fig. 1).
The authors of the HPS trial noted a substantial decrease in the
elative but not absolute benefit of simvastatin as NT-proBNP
ncreased. The authors of the CORONA study extend this
bservation into a higher range of NT-proBNP and suggest a
urther decrease in benefit from statins with greater levels.
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Figure 1 Relationship Between Plasma Concentrations ofNT-proBNP and CV Events in the HPS and CORONA Studies
Event rates are derived from the HPS (Heart Protection Study) trial except for
the final group, in which data are derived from patients with the highest tertile
of amino-terminal pro-brain natriuretic peptide (NT-proBNP) in the CORONA
(Controlled Rosuvastatin Multinational Study in Heart Failure) study. Assay
units have been converted to the equivalent with the Roche assay in picograms
per milliliter. Median and interquartile range (IQR) (in parentheses) in the HPS
trial were 168 pg/ml (58 to 422 pg/ml) and in the CORONA study were 1,438
pg/ml (600 to 3,214 pg/ml). CV  cardiovascular.amples were assayed.
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ardiac Rehabilitation
nd Prevention of
ardiovascular Disease
Role for Autonomic
ardiovascular Regulation
t is with interest that we read the state-of-the-art paper on cardiac
ehabilitation by Dr. Wenger (1). The article focuses on several
mportant issues related to exercise training and quoted a number
f factors that can contribute to the benefits of exercise training in
meliorating cardiovascular risk level, ranging from improvement
n lipid profile and endothelial function to a more favorable
brinolytic balance and anti-inflammatory action. We believe that
t also is important to mention the potential benefits of exercise
raining on autonomic cardiovascular regulation. Patients with
eart disease are at risk for life-threatening arrhythmias and
udden death, and it is well documented that alterations in the
eural control of the heart characterized by decreased vagal activity
nd concurrent sympathetic predominance may have a critical role
n the occurrence of arrhythmic events (2). A reduced baroreflex
ensitivity (BRS), a measure of baroreceptor reflex vagal control of
eart rate, has an independent prognostic value for cardiac mor-
ality and cardiac events after myocardial infarction (3). The
egative prognostic role of a depressed BRS and of an impaired
utonomic control of the heart extends to patients with heart
ailure (4).
Several studies have indicated that exercise training improves
RS and heart rate variability parameters in different populations
f cardiac patients, from post-myocardial infarction to coronary
rtery bypass graft surgery and heart failure (5–9), for whom, in all,
xercise training is highly recommended (1). Notably, improve-
ent in BRS by exercise training was related to a greater 10-year
urvival rate after myocardial infarction (10). These findings could
y now be considered consolidated experimental evidences. Car-
iac rehabilitation also improves depression and stress, with
dditional potential benefits on autonomic risk profile.
We believe that physicians should be informed on studies
emonstrating the beneficial effects of exercise training on auto-
omic cardiovascular regulation, particularly those who are not
amiliar with this topic. Stressing the beneficial effects of exercise
raining on autonomic cardiovascular risk profile would contribute
o boost further referral for cardiac rehabilitation by health care
rofessionals. (Ferdinando Iellamo, MD
assimo Pagani, MD, FACC
aurizio Volterrani, MD
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)
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eply
r. Iellamo and colleagues have provided an excellent summary of
he beneficial effects of exercise training on autonomic cardiovas-
ular regulation in response to my article (1). It is well accepted
hat reduced baroreflex sensitivity and impaired heart rate auto-
omic control negatively impact the prognosis of coronary heart
isease and other cardiovascular illnesses. However, the improve-
ent in baroreflex sensitivity and in parameters of heart rate
ariability in association with exercise training and their relation-
hip to improved cardiovascular prognosis cannot be attributed
olely to the exercise training component of cardiac rehabilitation,
lthough they are likely substantially mediated by exercise training.
Cardiac rehabilitation is a multifactorial intervention that in-
olves, in addition to prescribed exercise, cardiac risk factor
odification and multiple components of education and counsel-
ng; these concomitant processes are designed to limit the adverse
hysiological and psychological effects of cardiac illness, reduce the
isk of sudden death or reinfarction, control cardiac symptoms,
tabilize or reverse progression of the atherosclerotic process, and
nhance the psychosocial and vocational status of selected patients
2). Because this panoply of interventions, including the medical
